[{"id":"f86fbabb-dbbe-4ed0-8d46-9e3047621d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114668","created_at":"2021-11-10T14:12:50.487Z","updated_at":"2024-07-02T16:35:47.602Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05114668","lead_sponsor":"Kazia Therapeutics Limited","biomarkers":" FLT4","pipe":"","alterations":" ","tags":["FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EVT801"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-05-19"}]